Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Operating Leases (2020 - 2025)

Lexaria Bioscience's Operating Leases history spans 5 years, with the latest figure at $70819.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 30.52% year-over-year to $70819.0; the TTM value through Nov 2025 reached $70819.0, down 30.52%, while the annual FY2025 figure was $78903.0, 27.82% down from the prior year.
  • Operating Leases for Q4 2025 was $70819.0 at Lexaria Bioscience, down from $78903.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $116586.0 in Q2 2025 and bottomed at $18339.0 in Q2 2022.
  • The 4-year median for Operating Leases is $70819.0 (2025), against an average of $72696.5.
  • The largest annual shift saw Operating Leases soared 38.71% in 2021 before it tumbled 69.52% in 2022.
  • A 4-year view of Operating Leases shows it stood at $49989.0 in 2021, then crashed by 63.31% to $18339.0 in 2022, then soared by 455.76% to $101920.0 in 2024, then tumbled by 30.52% to $70819.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Operating Leases are $70819.0 (Q4 2025), $78903.0 (Q3 2025), and $116586.0 (Q2 2025).